JP2019512523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512523A5 JP2019512523A5 JP2018549788A JP2018549788A JP2019512523A5 JP 2019512523 A5 JP2019512523 A5 JP 2019512523A5 JP 2018549788 A JP2018549788 A JP 2018549788A JP 2018549788 A JP2018549788 A JP 2018549788A JP 2019512523 A5 JP2019512523 A5 JP 2019512523A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antagonist
- administered
- cancer
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006495 integrins Human genes 0.000 claims description 42
- 108010044426 integrins Proteins 0.000 claims description 42
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 20
- 238000002619 cancer immunotherapy Methods 0.000 claims description 19
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 12
- 229960003301 nivolumab Drugs 0.000 claims description 11
- 229960005386 ipilimumab Drugs 0.000 claims description 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229960004914 vedolizumab Drugs 0.000 claims description 7
- 229940121697 CD27 agonist Drugs 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 108091008042 inhibitory receptors Proteins 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 2
- 229940122558 EGFR antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 2
- 101150069255 KLRC1 gene Proteins 0.000 claims description 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical group NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 208000022136 colorectal lymphoma Diseases 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000001839 endoscopy Methods 0.000 claims description 2
- 229950006370 epacadostat Drugs 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001037 lung lymphoma Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 229920001184 polypeptide Polymers 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 230000036039 immunity Effects 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076211A JP7560508B2 (ja) | 2016-03-24 | 2022-05-02 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| JP2024161954A JP2024175093A (ja) | 2016-03-24 | 2024-09-19 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312671P | 2016-03-24 | 2016-03-24 | |
| US62/312,671 | 2016-03-24 | ||
| PCT/US2017/024033 WO2017165778A1 (en) | 2016-03-24 | 2017-03-24 | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076211A Division JP7560508B2 (ja) | 2016-03-24 | 2022-05-02 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512523A JP2019512523A (ja) | 2019-05-16 |
| JP2019512523A5 true JP2019512523A5 (https=) | 2020-05-07 |
| JP7069032B2 JP7069032B2 (ja) | 2022-05-17 |
Family
ID=58489432
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549788A Active JP7069032B2 (ja) | 2016-03-24 | 2017-03-24 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| JP2022076211A Active JP7560508B2 (ja) | 2016-03-24 | 2022-05-02 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| JP2024161954A Pending JP2024175093A (ja) | 2016-03-24 | 2024-09-19 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076211A Active JP7560508B2 (ja) | 2016-03-24 | 2022-05-02 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| JP2024161954A Pending JP2024175093A (ja) | 2016-03-24 | 2024-09-19 | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11760803B2 (https=) |
| EP (1) | EP3433275A1 (https=) |
| JP (3) | JP7069032B2 (https=) |
| MA (1) | MA44483A (https=) |
| WO (1) | WO2017165778A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250902T1 (hr) * | 2015-11-18 | 2025-09-26 | Bristol-Myers Squibb Company | Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela |
| MA44483A (fr) * | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
| CN109414502A (zh) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | 治疗炎症性肠病的方法 |
| AU2019216228A1 (en) * | 2018-02-02 | 2020-08-13 | Children's Research Institute, Children's National Medical Center | Methods of selecting and designing safer and more effective anti-CTLA-4 antibodies for cancer therapy |
| GB201913988D0 (en) * | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| AU2022297690A1 (en) * | 2021-06-21 | 2024-02-08 | Everimmune | Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapy |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US748802A (en) | 1904-01-05 | Territory | ||
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| DK1712623T3 (da) | 1997-01-21 | 2012-02-06 | Gen Hospital Corp | Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7322582B2 (en) | 2003-07-17 | 2008-01-29 | Mind Wurx, Llc | Enhanced shopping cart with lowered center of gravity and frame therefor |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| BRPI0514259A (pt) | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| RS52213B (sr) | 2004-09-03 | 2012-10-31 | Genentech, Inc. | Humanizovani anti-beta7 antagonisti i njihove primene |
| US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
| BRPI0710011A2 (pt) | 2006-04-14 | 2011-08-02 | Trubion Pharmaceuticals Inc | proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| JP2011506436A (ja) | 2007-12-12 | 2011-03-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US7993640B2 (en) | 2008-08-06 | 2011-08-09 | Light Sciences Oncology, Inc. | Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP3165540A1 (en) | 2010-04-13 | 2017-05-10 | Celldex Therapeutics, Inc. | Antibodies that bind human cd27 and uses thereof |
| WO2012027536A1 (en) | 2010-08-26 | 2012-03-01 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| WO2013019620A2 (en) | 2011-07-29 | 2013-02-07 | Glaxosmithkline Llc | Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| WO2013142796A2 (en) | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| US20140323533A1 (en) | 2013-04-29 | 2014-10-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| WO2015058048A1 (en) | 2013-10-18 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| MX385194B (es) | 2014-02-21 | 2025-03-14 | Nektar Therapeutics India Pvt Ltd | Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. |
| UY36046A (es) | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| PT3142751T (pt) | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| EP3012270A1 (en) | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| JP6904905B2 (ja) | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| CA2984316A1 (en) * | 2015-04-29 | 2016-11-03 | Darren G. Woodside | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| MA44483A (fr) * | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
-
2017
- 2017-03-24 MA MA044483A patent/MA44483A/fr unknown
- 2017-03-24 EP EP17715881.3A patent/EP3433275A1/en active Pending
- 2017-03-24 JP JP2018549788A patent/JP7069032B2/ja active Active
- 2017-03-24 WO PCT/US2017/024033 patent/WO2017165778A1/en not_active Ceased
- 2017-03-24 US US16/087,246 patent/US11760803B2/en active Active
-
2022
- 2022-05-02 JP JP2022076211A patent/JP7560508B2/ja active Active
-
2023
- 2023-07-20 US US18/355,975 patent/US12590157B2/en active Active
-
2024
- 2024-09-19 JP JP2024161954A patent/JP2024175093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512523A5 (https=) | ||
| JP7560508B2 (ja) | がん免疫治療における胃腸の免疫関連有害事象の治療方法 | |
| JP2024037894A5 (https=) | ||
| JP2017514461A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2020114241A5 (https=) | ||
| FI3310814T3 (fi) | HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ | |
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| RU2017102926A (ru) | Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов мек | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2011518546A5 (https=) | ||
| RU2017119428A (ru) | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit | |
| JP2019516394A5 (https=) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| HRP20140244T1 (hr) | Sastavi i metode za inhibiranje pdgfrbeta i vegf-a | |
| JP2015506945A5 (https=) | ||
| JP2016519650A5 (https=) | ||
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP2025118688A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2012505227A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| WO2017165742A1 (en) | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments | |
| JP2019528046A5 (https=) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever |